tbuckley/cabot-search huggingface dataset:
Dose-dependent bronchospasm from sulfites in isoetharine
Authors: J. W. Koepke
Journal: JAMA (1984)

ADVERSE reactions to sulfiting agents used as preservatives in foods and medications are being reported with increasing frequency.<sup>1</sup>Many bronchodilator solutions contain sulfites as antioxidants. We have previously called attention to the fact that sulfite-preserved bronchodilator solutions will liberate sulfur dioxide when nebulized.<sup>2</sup>Since the asthmatic airway has a heightened reactivity to sulfur dioxide, such exposure could place the asthmatic patient at risk.<sup>3</sup>This article describes an asthmatic patient who experienced a paradoxical response to isoetharine containing sodium bisulfite as preservative. <h3>Report of a Case</h3> The patient was a 31-year-old aspirin-sensitive asthmatic woman whose condition was first diagnosed when she was 9 years of age. In addition to bronchodilators, she had been taking daily steroids since the age of 10 years. Between 1972 and 1975, the patient experienced four episodes of severe wheezing following the ingestion of dried apricots, wine, a restaurant salad, and guacamole dip. The
Discovering Genes Essential to the Hypothalamic Regulation of Human Reproduction Using a Human Disease Model: Adjusting to Life in the “-Omics” Era
Authors: M. I. Stamou, K. H. Cox, William F. Crowley
Journal: Endocrine Reviews (2016)

The neuroendocrine regulation of reproduction is an intricate process requiring the exquisite coordination of an assortment of cellular networks, all converging on the GnRH neurons. These neurons have a complex life history, migrating mainly from the olfactory placode into the hypothalamus, where GnRH is secreted and acts as the master regulator of the hypothalamic-pituitary-gonadal axis. Much of what we know about the biology of the GnRH neurons has been aided by discoveries made using the human disease model of isolated GnRH deficiency (IGD), a family of rare Mendelian disorders that share a common failure of secretion and/or action of GnRH causing hypogonadotropic hypogonadism. Over the last 30 years, research groups around the world have been investigating the genetic basis of IGD using different strategies based on complex cases that harbor structural abnormalities or single pleiotropic genes, endogamous pedigrees, candidate gene approaches as well as pathway gene analyses. Although such traditional approaches, based on well-validated tools, have been critical to establish the field, new strategies, such as next-generation sequencing, are now providing speed and robustness, but also revealing a surprising number of variants in known IGD genes in both patients and healthy controls. Thus, before the field moves forward with new genetic tools and continues discovery efforts, we must reassess what we know about IGD genetics and prepare to hold our work to a different standard. The purpose of this review is to: 1) look back at the strategies used to discover the "known" genes implicated in the rare forms of IGD; 2) examine the strengths and weaknesses of the methodologies used to validate genetic variation; 3)substantiate the role of known genes in the pathophysiology of the disease; and 4) project forward as we embark upon a widening use of these new and powerful technologies for gene discovery. (Endocrine Reviews 36: 603-621, 2015).
Abstract 3460: Molecular Characterization, Safety and Feasibility of Induced Pluripotent Stem (iPS) Cell Derived Cardiomyocytes for Heart Regenerative Therapy
Authors: Yohei Ohno, Shinsuke Yuasa, Takeshi Onizuka, Toru Egashira, Kenichiro Shimoji, Sung Han Yoon, Takahide Arai, Jin Endo, Toshimi Kageyama, Hao Chen, Tomofumi Tanaka, Fumiyuki Hattori, Satoshi Ogawa, Shinya Yamanaka, Keiichi Fukuda
Journal: Circulation (2008)

[Background] We recently reported that mouse and human iPS cells could be generated from somatic cells by gene transfer of Oct3/4, Sox2, c-Myc and Klf4. Although the morphology, growth characteristics and pluripotency of iPS cells are believed to be similar to those of ES cells, there are several versions such as Fbx-iPS, Nanog-iPS cells, and it remains unknown whether what type of iPS cell could be appropriate for the cardiovascular regeneration therapy. This study investigated the cardiomyocyte differentiation potential of mouse iPS cells, molecular characterization of iPS-induced cardiomyocytes, and the safety and feasibility of their transplantation into the heart. [Methods and Results] We used several lines of Fbx-iPS and Nanog-iPS cells and induced cardiomyocyte differentiation using the hanging drop culture method. Mouse ES cells were used as control. Both Fbx-iPS and Nanog-iPS cells could differentiate into cardiomyocytes, and the incidence of beating embryoid bodies was similar to that of ES cells. RT-PCR analyses and immunohistochemistry revealed that both iPS cells expressed all the cardiomyocyte marker genes including Nkx2.5, GATA4, MEF2C, myosin light chain-2v, α-myosin heavy chain, atrial natriuretic peptide, and α-sarcomeric actinin, and they showed normal structures. Electron microscopic study revealed that iPS cell derived cardiomyocytes had the typical morphological cardiomyocyte structure, which is difficult to distinguish from that of ES cell derived cells. Electrical physiological study showed that iPS cell derived cardiomyocytes had sinus node-like or fetal ventricular type action potentials. Purified iPS cell derived cardiomyocytes could be successfully transplanted into murine hearts and the engrafted cells survived and were integrated into host myocardium. Nanog-iPS cell derived cells showed no severe complication after transplantation, however Fbx-iPS cell derived cells showed teratoma in the host tissue. Fbx-iPS cells expressed extrinsic c-myc after differentiation. [Conclusions] The iPS cells proved to be an attractive cell source for the regeneration of cardiomyocytes, however safety and careful characterization is necessary before clinical application.
Corrigendum
Authors: * Potassa Sulphurata, Potassii Bicarbonas, Potassii Potassii, Potassii Nitras Propamidine, Ipomea Kino, Krameria Lobelia, Oleum Anethi, Oleum Cinnamomi, Oleum Hydnocarpi, Oleum Limonis, Oleum Terebinthinae
Journal: BMJ (1944)

Prostigmine *Sodii diphenylhydan-Phenytoinum solu- toinas bile is identical
Archives of Surgery, Chicago
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Esophageal ulcers associated with tetracycline therapy
Authors: T. D. Crowson
Journal: JAMA (1976)

Esophageal ulceration has rarely been reported secondary to medicinal agents. We have treated three patients with esophageal ulceration associated with the ingestion of tetracycline or its derivative doxycycline. In light of the strong temporal relationship between taking the capsules and the onset of the esophageal ulceration, we believe that the capsules were the cause of the ulcers. We therefore recommend an alternative agent to tetracycline or doxycycline, if possible, for patients with any esophageal obstructive element. We also recommend that patients be cautioned not to take these drugs within one hour of going to bed. (<i>JAMA</i>235:2747-2748, 1976)
Frozen Sections
Authors: D. H. Patey
Journal: BMJ (1967)

<h3>BACKGROUND:</h3> Noninvasive respiratory support has become more popular in the pediatric population and may prevent or replace invasive procedures, such as endotracheal intubation, in certain circumstances. The objective was to examine the frequency of invasive and noninvasive respiratory support from 2009 to 2017 in critically ill pediatric patients and to determine patient-related factors associated with invasive support using the Virtual Pediatric Systems, LLC database. <h3>METHODS:</h3> This was an analysis of prospectively collected data on admissions with respiratory support from 17 pediatric ICUs from 2009 to 2017 reported within the Virtual Pediatric Systems database. We determined the frequency of invasive and noninvasive respiratory support over the study period by measuring the number of admissions with either invasive or noninvasive support within a given year divided by the total number of pediatric ICU admissions with respiratory support during the same year. Factors associated with invasive support were examined in univariate and multivariate regressions. <h3>RESULTS:</h3> A total of 69,262 cases of respiratory support were included. There was a decrease in the rate of invasive support over the study period from 66.9% to 48.5% (<i>P</i> value for test of trend &lt; .001) and an increase in the rate of noninvasive support from 28.7% to 57.7% (<i>P</i> value for test of trend &lt; .001). Trauma cases and subjects &lt; 1 month old were more likely to receive invasive support. Cases occurring in later years and subjects with Black or Hispanic race were less likely to receive invasive support. <h3>CONCLUSIONS:</h3> From 2009 to 2017, the frequency of admissions with invasive respiratory support decreased, and those with noninvasive respiratory support increased. By 2017, the frequency of noninvasive respiratory support was greater than that of invasive respiratory support.
Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.
Authors: Ellen Leich, Itziar Salaverria, Silvia Bea, Andreas Zettl, Randy D. Gascoyne, Wing-Chung Chan, Rita M. Braziel, Lisa M. Rimsza, Dennis D. Weisenburger, Jan Delabie, Elaine S. Jaffe, Thomas A. Lister, Andrew J. Norton, Louis M. Staudt, Elena M. Hartmann, Hans-Konrad Mueller-Hermelink, Elias Campo, German Ott, Andreas Rosenwald
Journal: Blood (2007)
THE NETHERLANDS
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Male pattern alopecia regrowth following topical fluorouracil therapy
Authors: R. L. Rietschel
Journal: JAMA (1977)

<h3>To the Editor. —</h3> We wish to report a patient thought to have male pattern baldness for ten years; he began to regrow terminal hair after his scalp was treated with fluorouracil for actinic keratosis. <h3>Report of a Case.—</h3> The patient is a 45-year-old man who had been bald in a frontoparietal distribution for ten years when seen on Sept 27, 1976, at the Dermatology Clinic, Brooke Army Medical Center. He had multiple actinic keratoses of the scalp and was treated with 2% fluorouracil (Efudex) solution followed in ten minutes with 0.5% triamcinolone acetonide cream daily.<sup>1</sup>When seen on Oct 18, 1976, after 21 days of treatment, a confluent, brisk erythema and edema engulfed the scalp, nose, and temples. The fluorouracil therapy was discontinued, and the reaction subsided after three weeks of 0.5% triamcinolone therapy. The patient was not seen again until March 10, 1977, when he returned specifically
The Traumatic Neuroses of War
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Should prophylactic antiarrhythmic drug therapy be used in acute myocardial infarction?
Authors: D. C. Harrison
Journal: JAMA (1982)

FOLLOWING acute myocardial infarction, death generally results from two pathophysiological processes. In the period early after infarction, electrical processes such as primary ventricular fibrillation (fibrillation unassociated with heart failure or cardiogenic shock) accounts for the largest percentage of deaths. These deaths occur primarily in the first 24 hours after infarction and occur with a higher frequency during the first four hours from the onset of chest pain and with decreasing frequency through the next 20 hours. Later deaths from acute myocardial infarction may also be electrical. However, a mechanical process, defined as cardiogenic shock, congestive heart failure, or both owing to extensive necrosis of muscle and loss of the mechanical function of the heart, may account for many of these deaths. The final common pathway for many of these pump failures is also ventricular fibrillation (defined as secondary ventricular fibrillation). Unlike primary ventricular fibrillation, a significant fraction of deaths in
Diagnostic evaluation of headache. Impact of computerized tomography and cost-effectiveness
Authors: E. B. Larson
Journal: JAMA (1980)

One hundred sixty-one highly selected patients with headache were studied to assess the impact of computerized tomography (CT) on diagnostic evaluation and to determine cost-effectiveness of neurodiagnostic evaluation of headache. Fewer nuclide brain scans were performed after availability of CT, but diagnostic charges stayed about the same. A careful history and physical and neurological examinations were adequate screens to detect intracranial mass lesions or systemic disease associated with headache. In patients with normal findings from neurological examination, no clinically important abnormalities were detected by CT, skull roentgenogram, angiography, or nuclide brain scan. The cost of finding a case of brain tumor was estimated to be at least $1,265 for patients with abnormalities on neurological examination and $11,901 for patients with normal findings on neurological examination. Neurodiagnostic evaluation of headache patients with normal findings from neurological examination is expensive and was clinically unrewarding in this series. (<i>JAMA</i>243:359-362, 1980)
Wants Cerebrine.
Authors: Archie Stockwell
Journal: JAMA (1893)

<h3>To the Editor—Dear Sir:</h3> —Will you kindly insert the communication herewith transmitted, in your correspondence column, and oblige. Very truly yours, G.Archie Stockwell. 650 Congress street, E. Detroit, Mich. <h3>$5.00 Reward.</h3> —The undersigned will pay $5.00 each for a few bottles of cerebrine (Hammond) of the lot issued by the Columbian Chemical Co. in May, 1893. This cerebrine was devoid of sophistication by nitroglycerin, and moreover did not have the label of the Columbian Chemical Co.,. cross-stamped by fac simile in red of Hammond's signature. Address 650 Congress street, E. Detroit, Mich.
DIAGNOSIS AND MANAGEMENT OF INTRATHORACIC GOITERS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of Fibromyalgia
Authors: Lawrence J. Leventhal
Journal: Annals of Internal Medicine (1999)

Despite extensive clinical study, there is no distinct consensus on the optimal management of fibromyalgia. The cause of fibromyalgia has not been clearly defined, but several mechanisms may be involved. Abnormalities in sleep patterns, muscle structure, and cerebral blood flow have been associated with the syndrome, but it is unclear whether a causal relation exists between these abnormalities and fibromyalgia. Recent evidence suggests that alterations in the metabolism and function of the neurotransmitters serotonin, norepinephrine, and substance P may contribute to the development of fibromyalgia. No pharmacologic agents are indicated specifically for the treatment of fibromyalgia in the United States, and most pharmacologic therapies show only limited success, although drugs that affect serotonin or norepinephrine at the receptor site (such as antidepressants or tramadol) seem to generate the most consistent results. Tricyclic antidepressants may diminish the sleep disturbance and pain caused by fibromyalgia, whereas selective serotonin reuptake inhibitors may be more useful for sleep and coexistent depression only. Among the commonly used analgesics, preliminary data suggest that tramadol may be useful for treatment of fibromyalgia pain and that trigger-point injections may be helpful. Controlled trials of anti-inflammatory agents have demonstrated little usefulness of these drugs, and oral opioids have not been studied for this condition. Miscellaneous agents, such as growth hormone, tropisetron or ondansetron, 5-hydroxytryptophan, γ-hydroxybutyrate, and S-adenosyl- l-methionine, have also shown promising preliminary results, but their clinical roles remain to be defined. Nonpharmacologic interventions (such as exercise, biofeedback, and electroacupuncture) have likewise shown some success. Therefore, a multidisciplinary approach that includes both pharmacologic and nonpharmacologic strategies is recommended.
Masthead
Authors: H Epato Logy, Vicente Arroyo, Ding-Shinn Chen, Nelson Fausto, Richard Green, Roberto Groszmann, West Em, Hartmut Jaexhke, Az Tucson, Lian Jake, Anna Beth&, Ann Lot, Arthur Ador, Jean-Michel Mccullough, Jan& Reddy, Don Rockey, Clifford Durham, Michael Steer, Paul Abecassis, Jeffrey London, Frank Albrecht, Atlanta Anania, Thomas Baumen, Abraham Bauiita, Pierre Bedossa, Henry Bodenheimer, New York, Thomas Boyer, Jordi Bruix, Jens Bukh, Roger Butterworth, Montreal Canah, Kyong-Mi Chang, Michael Charlton, Pei-Jer Chen, John Chiang, Jayanta Chowdhury, Pierre-Alain Clavien, Bruno Swirzrrland, David Clement, Massimo Cohen, Itab Milan, Antonio Robert Costa, Mark Craxi, Gennaro Czaja, Christopher Day, Bruce Bacon, St Louis, Teresa Wright, Sun Fruncisco, Charles Quesenberry, Ouklad Ca, Aodrat Wcb+bil, Harvey Alter, Elwyn Elias, Neil Kaplowia, Los Angeh, Hepatology Elsewhere, Hanmut Jaeschke, Kevin Mullen, Darius Moradpour, Germany Ednrnulbolud, Robert Deman, Netherlad, Adrian Dibisceglie, Michael Fallon, Geoffrey Farrell, Austrdiu Flye, Peter Gal, $ Maine, Alexander Gerbes, Frank Gonzalez, Markus Grompe, Portlad Or, Sanjeev Gupta, Ny Jenny, Heathcote Toronto, Setsuo Hirohashi, Ja Hoofnagle, John Iredale, Patrick Kamath, Saul Karpen, Emmet Houston, Stanfir4 Keeffe, Kazuhiko Ca, J Koziel, Franf Lammen, Alex Lenrxh, Yun-Fan Liaw, Taiwan Jac, J Maher, Gijio Marchesini, Roben Mccuskey, O Az, Adrian Reuben, Irwin Arias, Steven Schenker, Sun Antonio, Paul Berk, Ny Montgomery Bissell, Sun Francisco, Gregory Bologna, Lynn Price, Eunice Chege, Nicole Gauvin, Vikki Webster, John Mchutchison, Dirk Meijer, Carlo Merkel, Tatsuo Miyamura, Jupun Tokyo, Michael Nathanson, M Omary, Palo Alto, James Ou, Lor Angeh, David Perlmutter, Massimo Pinzani, Stephen Florence
Journal: Hepatology (2004)
THE HEALTH OF CHILDREN IN INSTITUTIONS
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal